2,4-dimethyl-N-[4-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-pyridinyl]-1,3-oxazole-5-carboxamide
C22H17N7O2 — CID 118162656
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2,4-dimethyl-N-[4-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-pyridinyl]-1,3-oxazole-5-carboxamide
2,4-dimethyl-N-[4-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-pyridinyl]-1,3-oxazole-5-carboxamide (PubChem CID 118162656) has the molecular formula C22H17N7O2 and a molecular weight of 411.43 g/mol. Its IUPAC name is 2,4-dimethyl-N-[4-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-pyridinyl]-1,3-oxazole-5-carboxamide.
Molecular Properties
| Compound Name | 2,4-dimethyl-N-[4-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-pyridinyl]-1,3-oxazole-5-carboxamide |
|---|---|
| PubChem CID | 118162656 |
| Molecular Formula | C22H17N7O2 |
| Molecular Weight | 411.43 g/mol |
| Exact Mass | 411.14 |
| IUPAC Name | 2,4-dimethyl-N-[4-(6-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-pyridinyl]-1,3-oxazole-5-carboxamide |
| SMILES | Cc1nc(C)c(C(=O)Nc2cc(-c3nc4ncc(-c5ccccc5)cn4n3)ccn2)o1 |
| InChI | InChI=1S/C22H17N7O2/c1-13-19(31-14(2)25-13)21(30)26-18-10-16(8-9-23-18)20-27-22-24-11-17(12-29(22)28-20)15-6-4-3-5-7-15/h3-12H,1-2H3,(H,23,26,30) |
| InChIKey | RIAXVYDXFXYHMK-UHFFFAOYSA-N |
| XLogP | 3.71 |
| TPSA | 111.10 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 411.43 |
| LogP ≤ 5 | 3.71 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118162656 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.